Madrigal Pharmaceuticals Inc (MDGL.OQ)
15 Dec 2017
Get access to over 18 million research reports from over 1,700 sources.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
- private equity
- third-party document and information retrieval
- and much, much more…
|74||2016||Chairman of the Board, Chief Executive Officer|
|65||2016||Founder, Chief Medical Officer, Executive Vice President, Research & Development and Director|
|63||2014||Chief Financial Officer, Senior Vice President|
|70||2016||Lead Independent Director|
- BRIEF-Madrigal's MGL-3196 Achieves Primary Endpoint In Patients With Biopsy-Proven Non-Alcoholic Steatohepatitis In Phase 2 Clinical Trial
- BRIEF-Madrigal Pharmaceuticals reports Q3 loss per share of $0.68
- BRIEF-Madrigal Pharmaceuticals announces outcome from pre-planned DSMB safety review and completion of enrollment of phase 2 study of MGL-3196
- BRIEF-Madrigal Pharmaceuticals reports qtrly loss per share $0.69
- BRIEF-Madrigal Pharma completes Phase 2 enrollment for study on treatment of NASH